S. Kopetz, G. Chang, M. Overman, C. Eng, D. Sargent et al., Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy, Journal of Clinical Oncology, vol.27, issue.22, pp.3677-3683, 2009.
DOI : 10.1200/JCO.2008.20.5278

T. André, C. Boni, M. Navarro, J. Tabernero, and T. Hickish, Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial, Journal of Clinical Oncology, vol.27, issue.19, pp.3109-3116, 2009.
DOI : 10.1200/JCO.2008.20.6771

J. Kuebler, H. Wieand, O. Connell, M. Smith, R. Colangelo et al., Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07, Journal of Clinical Oncology, vol.25, issue.16, pp.2198-2204, 2007.
DOI : 10.1200/JCO.2006.08.2974

J. Douillard, D. Cunningham, A. Roth, M. Navarro, and R. James, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, The Lancet, vol.355, issue.9209, pp.1041-1047, 2000.
DOI : 10.1016/S0140-6736(00)02034-1

L. Saltz, J. Cox, C. Blanke, L. Rosen, and L. Fehrenbacher, Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.343, issue.13, p.905, 2000.
DOI : 10.1056/NEJM200009283431302

D. Cunningham, S. Pyrhönen, R. James, C. Punt, and T. Hickish, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1413-1418, 1998.
DOI : 10.1016/S0140-6736(98)02309-5

P. Rougier, E. Van-cutsem, E. Bajetta, N. Niederle, and K. Possinger, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1407-1412, 1998.
DOI : 10.1016/S0140-6736(98)03085-2

A. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, and Y. Abubakr, EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.14, pp.2311-2319, 2008.
DOI : 10.1200/JCO.2007.13.1193

URL : https://hal.archives-ouvertes.fr/inserm-00484211

C. Tournigand, T. Andre, and E. Achille, FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2, p.229, 2004.
DOI : 10.1200/JCO.2004.05.113

M. Mabro, P. Artru, T. André, M. Flesch, and F. Maindrault-goebel, A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients, British Journal of Cancer, vol.24, issue.9, pp.1287-1292, 2006.
DOI : 10.1016/S0959-8049(98)00353-0

F. Bidard, C. Tournigand, T. André, M. Mabro, and A. Figer, Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study, Annals of Oncology, vol.20, issue.6, pp.1042-1047, 2009.
DOI : 10.1093/annonc/mdn730

E. Viel, M. Demarchi, L. Chaigneau, T. Nguyen, C. Legat et al., A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies, American Journal of Clinical Oncology, vol.31, issue.1, pp.89-94, 2008.
DOI : 10.1097/COC.0b013e318134ee9c

URL : https://hal.archives-ouvertes.fr/inserm-00483393

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, and J. Hainsworth, Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

V. Goede, O. Coutelle, J. Neuneier, A. Reinacher-schick, and R. Schnell, Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy, British Journal of Cancer, vol.63, issue.9, pp.1407-1414, 2010.
DOI : 10.1038/nm988

C. Jaxel, K. Kohn, and M. Wani, Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity, Cancer Res, vol.49, pp.1465-1469, 1989.

S. Guichard, D. Cussac, and I. Hennebelle, Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29in vitro andin vivo, International Journal of Cancer, vol.74, issue.5, pp.729-734, 1997.
DOI : 10.1002/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#

S. Guichard, I. Hennebelle, and R. Bugat, Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line, Biochemical Pharmacology, vol.55, issue.5, pp.667-676, 1998.
DOI : 10.1016/S0006-2952(97)00541-8

D. Mans, I. Grivicich, and G. Peters, Sequence dependent growth inhibition and DNA damage formation by the irinotecan-5fluorouracil combination in human colon carcinoma cell lines, Eur J Cancer, vol.13, pp.1851-1861, 1999.

M. Mabro, C. Louvet, and T. Andre, Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer, American Journal of Clinical Oncology, vol.26, issue.3, pp.254-258, 2003.
DOI : 10.1097/01.COC.0000020581.59835.7A

R. López, M. Salgado, M. Reboredo, C. Grande, and J. Méndez, A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer, British Journal of Cancer, vol.57, issue.10, pp.1536-1541, 2010.
DOI : 10.1200/JCO.2009.25.1991

S. Kopetz, P. Hoff, J. Morris, R. Wolff, C. Eng et al., Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance, Journal of Clinical Oncology, vol.28, issue.3, pp.453-459, 2010.
DOI : 10.1200/JCO.2009.24.8252

H. Hochster, Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer, Seminars in Oncology, vol.33, pp.8-14, 2006.
DOI : 10.1053/j.seminoncol.2006.08.005

C. Fuchs, J. Marshall, and E. Mitchell, Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study, Journal of Clinical Oncology, vol.25, issue.30, pp.4779-4786, 2007.
DOI : 10.1200/JCO.2007.11.3357

E. Van-cutsem, F. Rivera, S. Berry, A. Kretzschmar, and M. Michael, Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study, Annals of Oncology, vol.20, issue.11
DOI : 10.1093/annonc/mdp233

B. Chibaudel, F. Maindrault-goebel, . Lledo, L. Mineur, and T. André, Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5727-5733, 2009.
DOI : 10.1200/JCO.2009.23.4344

R. Adams, A. Meade, M. Seymour, R. Wilson, and A. Madi, Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for fi rst-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet Oncol, vol.12, pp.542-553, 2011.

A. Grothey, L. Hart, R. K. Ansari, R. Alberts, and S. , Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.4010

E. Díaz-rubio, A. Gómez-españa, B. Massutí, J. Sastre, and A. Abad, First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study, The Oncologist, vol.17, issue.1, pp.15-25, 2012.
DOI : 10.1634/theoncologist.2011-0249

G. Folprecht, A. Grothey, S. Alberts, H. Raab, and C. Köhne, Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates, Annals of Oncology, vol.16, issue.8, pp.1311-1319, 2005.
DOI : 10.1093/annonc/mdi246

G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, and C. Cremolini, Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, The Lancet Oncology, vol.11, issue.9, pp.845-852, 2010.
DOI : 10.1016/S1470-2045(10)70175-3

E. Volkova, J. Willis, J. Wells, B. Robinson, G. Dachs et al., Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer, British Journal of Cancer, vol.10, issue.1, pp.51-59, 2011.
DOI : 10.1016/j.bbrc.2005.06.014

C. Schliemann, R. Bieker, and N. Thoennissen, Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia, Leukemia, vol.93, issue.9, pp.1901-1906, 2007.
DOI : 10.1016/j.ccr.2004.09.030

I. Helfrich, L. Edler, and A. Sucker, Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma, Clinical Cancer Research, vol.15, issue.4, pp.1384-1392, 2009.
DOI : 10.1158/1078-0432.CCR-08-1615

G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, and M. Caruso, Phase III RANDOMIZED Trial of FOLFIRI Versus FOLFOX4 in the Treatment of http, pp.1471-2407611

R. Labianca, A. Sobrero, L. Isa, E. Cortesi, and S. Barni, Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial, Annals of Oncology, vol.22, issue.5, pp.1236-1242, 2011.
DOI : 10.1093/annonc/mdq580

M. Koopman, N. Antonini, J. Dourma, J. Wals, and A. Honkoop, Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, The Lancet, vol.370, issue.9582, pp.135-142, 2007.
DOI : 10.1016/S0140-6736(07)61086-1

M. Dureux, D. Malka, J. Mendiboure, P. Etienne, and P. Texereau, Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000???05): an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.12, issue.11, pp.1032-1044, 2011.
DOI : 10.1016/S1470-2045(11)70199-1

T. Maughan, R. Adams, C. Smith, A. Meade, and M. Seymour, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, The Lancet, vol.377, issue.9783, pp.2103-2114, 2011.
DOI : 10.1016/S0140-6736(11)60613-2

L. Saltz, S. Clarke, E. Dias-rubio, W. Scheithauer, and A. Figer, Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study, Journal of Clinical Oncology, vol.26, issue.12, pp.2013-2019, 2008.
DOI : 10.1200/JCO.2007.14.9930

H. Schmoll, D. Cunningham, A. Sobrero, C. Karapetis, and P. Rougier, Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III), Journal of Clinical Oncology, vol.30, issue.29, pp.3588-3595, 2012.
DOI : 10.1200/JCO.2012.42.5355

E. Van-cutsem, C. Köhne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1417, 2009.
DOI : 10.1056/NEJMoa0805019

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, and R. Burkes, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-4705, 2010.
DOI : 10.1200/JCO.2009.27.4860

C. Bokemeyer, I. Bondarenko, J. Hartmann, F. De-braud, and G. Schuch, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1546, 2011.
DOI : 10.1093/annonc/mdq632

G. Masi, E. Vasile, F. Loupakis, S. Cupini, and L. Fornaro, Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis, JNCI Journal of the National Cancer Institute, vol.103, issue.1, pp.21-30, 2011.
DOI : 10.1093/jnci/djq456

. Kim, Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels, BMC Cancer, vol.103, issue.1, p.611, 2013.
DOI : 10.1093/jnci/djq456

URL : https://hal.archives-ouvertes.fr/inserm-00922823